Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test Product 2 Clear all
Not listed Phase 2 Interventional

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

NCT01273337
View directory record Official record
Conditions
Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions
ALD-401, Sham Procedure
Biological · Procedure
Lead sponsor
Aldagen
Industry
Eligibility
30 Years to 83 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Results available

Loss of Resistance, w/wo Stimulation, For Epidural Placement

NCT03087604
View directory record Official record
Conditions
Anesthesia
Interventions
Thoracic epidural block, Electrical Nerve stimulation, Solution For Thoracic epidural block
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Preoperative Skin Preparation Evaluation

NCT00636480
View directory record Official record
Conditions
Topical Antisepsis
Interventions
Chlorhexidine gluconate, ChloraPrep One Step, Sterile saline
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
16 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 6, 2026, 3:06 AM EDT
Suspended Phase 1 Interventional

2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

NCT06626633
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CRD3874
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 6, 2026, 3:06 AM EDT
Recruiting Not applicable Interventional

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

NCT04199026
View directory record Official record
Conditions
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice, Everolimus, Ganitumab, Ifosfamide, Irinotecan, Pazopanib, Polyethylene Glycol, Temozolomide, Temsirolimus, Therapeutic Conventional Surgery, Vincristine
Drug · Device · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 6, 2026, 3:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Results available

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

NCT04039217
View directory record Official record
Conditions
ART, HIV
Interventions
Biktarvy
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 6, 2026, 3:06 AM EDT
Recruiting Phase 2 Interventional

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

NCT06769126
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
148
States / cities
Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 6, 2026, 3:06 AM EDT
Completed No phase listed Observational

Febrile Whole Blood Specimen Collection and Testing

NCT03498027
View directory record Official record
Conditions
Febrile Infection, Anthrax
Interventions
TaqMan Bacillus anthracis Detection Kit
Device
Lead sponsor
MRI Global
Industry
Eligibility
2 Years to 89 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 6, 2026, 3:06 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951
View directory record Official record
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

NCT02668653
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Chemotherapy, Quizartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 6, 2026, 3:06 AM EDT
Terminated Early Phase 1 Interventional Results available

Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice

NCT06312657
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Drug Cue, Money, Withdrawal, Remifentanil
Behavioral · Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 6, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional Results available

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

NCT04871529
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Early Phase 1 Interventional

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

NCT01894451
View directory record Official record
Conditions
Inflammatory Breast Carcinoma
Interventions
89Zr-bevacizumab, FDG-PET/CT, MRI scan, Tumor biopsies
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 6, 2026, 3:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
efalizumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation

NCT03861780
View directory record Official record
Conditions
Bacteria Microflora Reduction
Interventions
Project X 26ml, Project X 5.1ml, Prevantics Maxi Swabstick
Drug
Lead sponsor
Professional Disposables International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 6, 2026, 3:06 AM EDT
Terminated Phase 3 Interventional Results available

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer

NCT00093834
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, cyclophosphamide, doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 6, 2026, 3:06 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 6, 2026, 3:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03310619
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 6, 2026, 3:06 AM EDT
Not listed Not applicable Interventional

Transmission Reduction Intervention Project

NCT01827228
View directory record Official record
Conditions
HIV
Interventions
Assays, HIV medical care, Social network and venue tracing, Community alerts, Community education, HIV counseling
Other · Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 6, 2026, 3:06 AM EDT